UK-based gene and cell therapy developer Oxford Biomedica has teamed up with the biopharmaceutical firm PhoreMost to develop chimeric antigen receptor (CAR)-T cell therapies.

Under the agreement, PhoreMost will use its phenotype-screening platform to identify therapeutic candidates for Oxford Biomedica’s gene-therapy delivery system.

The companies said they will initially focus on CAR-T cell therapies but may branch out later into other types of cell therapies. Financial terms of the deal were not disclosed.